9T.C.Wascher T.Schmoelzer A wiegratz.降低糖耐量低减患者糖负荷后高血糖能够预防急性内皮细胞功能异常[J].European Journal of clinical investigation,2005,35:551-557.
10Chiasson JL, Gomis R, Hanefeld M. et al: for the STOP - NIDDM trial research group:Acarbose for prevention of type 2 diabetes mellitus:the STOP - NIDDM randomized triM: The Lancet 2002; 359 .- 2072 - 2077.
二级参考文献56
1[2]Report of Expert Committee onthe diagnosis and classification of diabetes mellitus.Diabetes Care 2001;24(Suppl 1):S5-S20.
2[4]Ceriello A. The postprandial state and the risk of atherosclerosis. Diabetes Care 1997; 23: S6 - 11.
3[5]Coutinho M, et al. The relationship between glucose and incident cardiovascular events. Diabetes Care 1999; 22 (2): 223- 240.
4[6]Lefebrre PJ, Scheen AJ. The postprandial State risk of Cardio Vascular disease. Diabet Med 1988; 15 (Suppl 4) : 363 -368.
5[7]Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non - insulin - dependent diabetes mellitus: a multicenter, controlled clinical trial [J].Ann Intern Med 1994;121:928.
6[8]Lkenoue T, Okazaki K, Fujitani S, et al. Effect of a new hypoglycemic agent, A - 4166 [ ( - ) - N - ( trans - 4 - isopropylcyclhexanecarbonyl) - D - phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide [J]. Biol Pharm Bull 1997;20(4) :354.
7[1]Monnier L, Lapinski H, Colette C. Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hvoerglveemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26(3) :881 -885.
8[2]Bell DS. Importance of postprandial glucose control.Southern med J 2001;94(8) :804 - 809.
9[3]Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):223-240.
10[4]Temelkova - Kurktschiev TS, Koehler C, Henkel E, et al.Postchallenge plasma glucose and glycemic spikes are more strongly associated with atheroscelerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23 (12): 1830 - 1834.
4AmlOv J, Ingelsson E, Sundstrom J, et al. Impact of bodymass index and the metabolic syndrome on the risk of cardi- ovascular disease and death in middle - aged men [ J ]. Cir- culation, 2010,121 ( 2 ) : 230 - 236.
5Kang G, Guo L, Guo Z, et al. Impact of blood pressure and other components of the metabolic syndrome on the develop- ment of cardiovascular disease[ J]. Circ J ,2010,74:456.
6Vacearino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program [ J ]. American Journal of Cardiology, 2001,88(9) :980 -986.
7UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 dia- betes: UKPDS 38[J]. BMI,1998,317:703.
8韦昭.糖尿病并发症的防治进展[J].中华实用心脑肺血管病杂志,2008,16(8).61-65.
9MATTEO A. Cardiovascular prevention in type 2 di- abetes mellitus patients:the role of oral glucose-low- ering agents J ]. J Diabetes Complications, 2009,23 (2) :427 -433.
10ZACCARDI F, PITOCCO D, GHIRLANDA G. Gly- cemic risk factors of diabetic vascular complications: the role of glycemic variability [ J ]. Diabetes MetabRes ,2009,25 ( 2 ) : 199 - 207.
